JP2020508655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508655A5 JP2020508655A5 JP2019544812A JP2019544812A JP2020508655A5 JP 2020508655 A5 JP2020508655 A5 JP 2020508655A5 JP 2019544812 A JP2019544812 A JP 2019544812A JP 2019544812 A JP2019544812 A JP 2019544812A JP 2020508655 A5 JP2020508655 A5 JP 2020508655A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- substantially similar
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 21
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 21
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 20
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 20
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 20
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 6
- 102000043321 human CTLA4 Human genes 0.000 claims 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461560P | 2017-02-21 | 2017-02-21 | |
| US62/461,560 | 2017-02-21 | ||
| PCT/US2018/012545 WO2018156250A1 (en) | 2017-02-21 | 2018-01-05 | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508655A JP2020508655A (ja) | 2020-03-26 |
| JP2020508655A5 true JP2020508655A5 (enExample) | 2021-02-12 |
| JP7165995B2 JP7165995B2 (ja) | 2022-11-07 |
Family
ID=63254023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544812A Active JP7165995B2 (ja) | 2017-02-21 | 2018-01-05 | 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11319372B2 (enExample) |
| EP (1) | EP3585430A4 (enExample) |
| JP (1) | JP7165995B2 (enExample) |
| CN (1) | CN110545844A (enExample) |
| WO (1) | WO2018156250A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375354B (es) | 2013-03-13 | 2025-03-06 | Prothena Biosciences Ltd | Anticuerpos que se unen a tau y usos de los mismos. |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EA201892412A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
| CA3022673A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| AU2017414149B2 (en) | 2017-05-19 | 2025-05-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| EP3902833A2 (en) | 2018-12-26 | 2021-11-03 | City of Hope | Activatable masked anti-ctla4 binding proteins |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN113597431B (zh) * | 2019-02-08 | 2025-02-21 | 普罗塞纳生物科学有限公司 | 识别Tau的抗体 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN119371527A (zh) | 2019-03-03 | 2025-01-28 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| US20230045494A1 (en) | 2020-02-28 | 2023-02-09 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| GB2611211A (en) | 2020-06-11 | 2023-03-29 | Nantbio Inc | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| CN113244389B (zh) * | 2021-07-06 | 2021-09-17 | 诺赛联合(北京)生物医学科技有限公司 | 一种TILs细胞制备方法及在肿瘤治疗的用途 |
| CN116440263A (zh) * | 2022-01-17 | 2023-07-18 | 上海君实生物医药科技股份有限公司 | 抗ctla-4抗体药物组合物及其用途 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| WO2025140296A1 (zh) * | 2023-12-26 | 2025-07-03 | 上海宏成药业有限公司 | 抗dll3抗体或其抗原结合片段及其用途 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026012032A1 (en) * | 2024-07-10 | 2026-01-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Antibodies against integrin and uses thereof |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130077A2 (hr) * | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
| AU2007249713A1 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists |
| US8263073B2 (en) * | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| CA2986765A1 (en) * | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
-
2018
- 2018-01-05 WO PCT/US2018/012545 patent/WO2018156250A1/en not_active Ceased
- 2018-01-05 CN CN201880026480.5A patent/CN110545844A/zh active Pending
- 2018-01-05 EP EP18757386.0A patent/EP3585430A4/en not_active Withdrawn
- 2018-01-05 JP JP2019544812A patent/JP7165995B2/ja active Active
- 2018-01-05 US US16/487,330 patent/US11319372B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019243665B2 (en) | Multivalent antibody | |
| JP2018522888A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2013545738A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2017526370A5 (enExample) | ||
| JP2023551027A5 (enExample) | ||
| US11319371B2 (en) | Anti-CD3 antibodies | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| JP2020514277A5 (enExample) | ||
| EP3684802A1 (en) | Novel stable antibody variable domain framework combinations | |
| US20220340677A1 (en) | Split intein and preparation method for recombinant polypeptide using the same | |
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| JP2013545455A5 (enExample) | ||
| RU2018137110A (ru) | Антитела против psma и их применение | |
| JP2022545647A5 (enExample) | ||
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| SI2699264T1 (en) | Antibodies and other molecules that bind b7-h1 and pd-1 | |
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| JP2012530487A5 (enExample) |